The study listed may include approved and non-approved uses, formulations or treatment regimens. The results reported in any single study may not reflect the overall results obtained on studies of a product. Before prescribing any product mentioned in this Register, healthcare professionals should consult prescribing information for the product approved in their country.

Statement of Discontinuation of the study	
Name of Company: GlaxoSmithKline Biologicals	
Study No: 111103 (EudraCT# 2007-006651-39)	
Product: SB580299	
Title: A phase IV, randomized, open-label, controlled, post-licensure study to evaluate the safety of GlaxoSmithKline Biologicals' HPV-16/18 L1 VLP AS04 vaccine (Cervarix) when administered intramuscularly according to a 0, 1, 6-month schedule in females aged 18-25 years.	
Phase: IV	
Study Period: May 2009 to September 2012	
Centres: NA	
Number of Subjects: 0	
Publications: NA	
Statement on discontinuation of the study: Discontinued by GlaxoSmithKline during preparation of the trial. No patient entered the study, therefore no results / data are available.	